EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Implementing response-adaptive randomisation in stratified rare-disease trials: Design challenges and practical solutions

Rajenki Das iD, Nina Deliu iD, Mark R Toshner, Sofía S Villar iD

Statistical Methods in Medical Research · 2026-11 · 35 (11) · 2347-2366

DOI: 10.1177/09622802251380625 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistical Methods in Medical Research, online erschienen am 06.10.2025. Verfasst von Rajenki Das und 3 weiteren Autor:innen. Beteiligte Einrichtung: MRC Biostatistics Unit, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Rare Diseases, Research Design, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Efficient Study Design, Cambridge NIHR Biomedical Research Centre, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although response-adaptive randomisation (RAR) has gained substantial attention in the literature, it still has limited use in clinical trials. Amongst other reasons, the implementation of RAR in real world trials raises important practical questions, often neglected in the technical literature. Motivated by an innovative phase-II stratified RAR rare-disease trial, this paper addresses two challenges: (1) How to ensure that RAR allocations are desirable, that is, both acceptable and faithful to the intended probabilities, particularly in small samples? and (2) What adaptations to trigger after interim analyses in the presence of missing data? To answer (1), we propose a Mapping strategy that discretises the randomisation probabilities into a vector of allocation ratios, resulting in improved frequentist errors. Under the implementation of Mapping , we answer (2) by analysing the impact of missing data on operating characteristics in selected scenarios. Finally, we discuss additional concerns including: pooling data across trial strata, analysing the level of blinding in the trial, and reporting safety results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesResearch DesignRandomized Controlled Trials as TopicClinical Trials, Phase II as TopicHumans

Stichwörter der Autor:innen

Adaptive designsadaptive randomisationimplementationmappingrare disease

Autor:innen und Institutionen

  • MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
  • MEMOTEF, Sapienza University of Rome, Roma, Italy.
  • Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, UK.
  • Royal Papworth Hospital, Cambridge, UK.

ORCID-Profile: Rajenki Das, Nina Deliu, Sofía S Villar

Förderung

  • Efficient Study Design
  • Cambridge NIHR Biomedical Research Centre
  • Medical Research Council

Zitieren

APA

Das, R., Deliu, N., Toshner, M. R., & Villar, S. S. (2026). Implementing response-adaptive randomisation in stratified rare-disease trials: Design challenges and practical solutions. Statistical Methods in Medical Research, 35(11), 2347-2366. https://doi.org/10.1177/09622802251380625

Vancouver

Das R, Deliu N, Toshner MR, Villar SS. Implementing response-adaptive randomisation in stratified rare-disease trials: Design challenges and practical solutions. Statistical Methods in Medical Research. 2026;35(11):2347-2366. doi:10.1177/09622802251380625

BibTeX
@article{Das2026,
  author = {Das, Rajenki and Deliu, Nina and Toshner, Mark R and Villar, Sofía S},
  title = {Implementing response-adaptive randomisation in stratified rare-disease trials: Design challenges and practical solutions},
  journal = {Statistical Methods in Medical Research},
  year = {2026},
  volume = {35},
  number = {11},
  pages = {2347--2366},
  doi = {10.1177/09622802251380625}
}
Kostenlos starten →